Dyslipidemia – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9 inhibitors, are used to improve lipid levels with the ultimate goal of CV risk reduction. Statins dominate the dyslipidemia market owing to their good risk-benefit profile and evidence for reducing CV morbidity and mortality. However, the later-line treatment paradigm is evolving owing to the emergence of novel drug classes and more-positive outcomes data for the established agents. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated dyslipidemia patients are treated in the United States.
What patient shares do key therapies and brands garner by line of therapy in newly diagnosed dyslipidemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed dyslipidemia patients?
How has Nexletol been integrated into the treatment algorithm, and what is its source of business?
What percentage of dyslipidemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of dyslipidemia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)
Treatment Algorithms CDA Dyslipidemia US March 2021
Treatment Algorithms CDA Dyslipidemia US 2021 Dashboard
Rohit Bansal, M.S. (Pharm.)
Rohit Bansal, M.S. (Pharm.), is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at DRG, part of Clarivate. He has authored several reports on metabolic indications, chiefly dyslipidemia and nonalcoholic steatohepatitis (NASH). Prior to joining DRG, he worked in a consultancy assisting various pharmaceutical companies. He earned his master’s degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research (NIPER) in India.